As of Oct 26, 2026: Cogent Biosciences (COGT) has a PDUFA date for bezuclastinib on Nov 30, 2026, in 35 days. Its Quality Score is 0. Scores as of 8:36 PM ET, 15 minutes behind.

COGT FDA decision on Bezuclastinib

Cogent Biosciences · PDUFA date

PDUFA dateNov 30in 35 days Quality Score0Below Average

Cash runway10quarters of cash

What the company said

“Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026”

PDUFA date, Nov 30, 2026. As Cogent Biosciences stated in its 8-K of Aug 10, 2026 (the filing).

A PDUFA date is the day the FDA has said it aims to decide on a drug. The FDA can decide earlier, or extend its review, often by three months.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Get an alert before COGT's FDA date

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

How COGT's stock moved on its past FDA days, for Pro members. Pro members also see whether its cash lasts past Nov 30, and the members' FDA calendar with filters and optional alerts.

More on COGT and the FDA calendar

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

The FDA calendar.